Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 38%
Buy 13%
Hold 13%
Sell 25%
Strong Sell 13%

Bulls say

Novavax is poised for success in the biotechnology market with its robust pipeline of high-value assets and potential for partnerships that will drive value creation for its novel vaccine technology. The company's recent collaboration with Sanofi has already resulted in $20 million in sales, further demonstrating the potential demand for its vaccine. With a differentiated tolerability profile and projected market share of 19-26% for its standalone COVID-19 vaccine, Novavax is well positioned for growth and has the potential to be a major player in the COVID-19 vaccine market.

Bears say

Novavax is a biotechnology company that is currently in its clinical stage of development, with a focus on developing novel vaccines for a wide range of diseases. The recent positive results from the COMPARE study, which compared its vaccine Nuvaxovid to mNEXSPIKE, have shown a potentially differentiated tolerability profile, supported by a 3rd party ICER draft evidence report. However, Novavax’s share in the vaccine market may be limited due to the competitive landscape and potential risks such as failure to successfully develop a combo vaccine, potential eradication of the virus, and negative regulatory developments. Additionally, Novavax’s long-term success hinges on the successful development and commercialization of its Matrix-M adjuvant technology.

Novavax (NVAX) has been analyzed by 8 analysts, with a consensus rating of Hold. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 25% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 8 analysts, Novavax (NVAX) has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.